{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:02:20Z","timestamp":1789754540887,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111482","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:40:47Z","timestamp":1772984447000},"page":"111482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer"],"prefix":"10.1016","volume":"219","author":[{"given":"Randal H.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis M.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"R.Charles","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-8217","authenticated-orcid":false,"given":"Perry B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kethandapatti C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy P.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111482_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline. Part III: Principles of Radiation and Future Directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111482_b0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate Cancer. Version 04.2024 May 17, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed May 31, 2024."},{"key":"10.1016\/j.radonc.2026.111482_b0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/0284186X.2021.2016948","article-title":"Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer","volume":"61","author":"Henderson","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2019.05.069","article-title":"Four-Year Outcomes from a prospective phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer","volume":"105","author":"Grewal","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111482_b0030","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/0284186X.2017.1287946","article-title":"Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer","volume":"56","author":"Henderson","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2010.09.024","article-title":"Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer","volume":"82","author":"Mendenhall","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2026.111482_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2019.01.091","article-title":"Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer","volume":"104","author":"Abu-Gheida","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109854","article-title":"Proton therapy for the management of localized prostate cancer: long-term clinical outcomes at a comprehensive cancer center","volume":"188","author":"Sosa","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0055","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ijrobp.2020.11.007","article-title":"Proton Therapy for Localized Prostate Cancer: Long-Term results from a Single-Center Experience","volume":"109","author":"Takagi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0060","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.ijrobp.2021.07.871","article-title":"10-Year Outcomes following Proton Therapy for Localized Prostate Cancer","volume":"111","author":"Bryant","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0065","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0070","first-page":"464","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"LancetOncol"},{"key":"10.1016\/j.radonc.2026.111482_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0080","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2009.01.062","article-title":"Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I\/II dose escalation study","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0090","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel Spacer prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate image Guided Intensity Modulated Radiation Therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bju.15821","article-title":"Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer","volume":"131","author":"Harvey","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111482_b0100","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.28536","article-title":"Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer","volume":"120","author":"Hoppe","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111482_b0105","first-page":"80","article-title":"Proton beam therapy delivered using pencil beam scanning vs. passive scattering\/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09. Clin Transl","volume":"19","author":"Mishra","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2021.06.023","article-title":"Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques","volume":"161","author":"Dee","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0115","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111482_b0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2017.01.009","article-title":"Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer","volume":"123","author":"Wang","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111482_b0125","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0","article-title":"Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma","volume":"79","author":"Neugut","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111482_b0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External Beam Radiotherapy increases the risk of Bladder Cancer when Compared with Radical Prostatectomy in patients Affected by Prostate Cancer: a Population-based Analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111482_b0135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V","article-title":"Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery","volume":"88","author":"Brenner","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111482_b0140","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2004.12.038","article-title":"Increased risk of rectal cancer after prostate radiation: a population-based study","volume":"128","author":"Baxter","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.radonc.2026.111482_b0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","article-title":"Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer","volume":"83","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111482_b0150","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1464-410X.2012.11385.x","article-title":"Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention","volume":"110","author":"Zelefsky","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111482_b0155","unstructured":"Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL). ClinicalTrials.gov identifier: NCT01617161. Updated January 22, 2026. Accessed January 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01617161."},{"key":"10.1016\/j.radonc.2026.111482_b0160","unstructured":"A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE). ClinicalTrials.gov identifier: NCT03561220. Updated September 9, 2025. Accessed January 30, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03561220?term=NCT03561220&rank=1&tab=study."},{"key":"10.1016\/j.radonc.2026.111482_b0165","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high risk prostate cancer: long term results of randomised controlled trails (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:04:32Z","timestamp":1789751072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0167814026001210"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111482","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111482"}}